Uganda Approves Twice-Yearly HIV PrEP

S 1 - 2 D I ID RK RT C - 0

Uganda approved Lenacapavir, a twice-yearly injectable HIV pre-exposure prophylaxis (PrEP), on January 5, 2026. Developed by US-based Gilead Sciences, the drug demonstrated 100% effectiveness in high-risk groups in clinical trials. Uganda aims to use it to help end AIDS by 2030, targeting key populations. The approval follows the IMPALA study in East and Southern Africa, which confirmed the effectiveness and acceptability of long-acting injectable HIV treatments compared with daily oral regimens.